anti-CD22 degrader-antibody conjugates (Genentech)

N/A

Report date: 2025/01/26 18:28:02

Base Information

Drug Nameanti-CD22 degrader-antibody conjugates (Genentech)
Drug Alias NameSMARCA2-degrading anti-CD22 antibody-drug conjugates (Genentech)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionCD22 modulatorsProbable global transcription activator SNF2L2 inhibitors
TargetsProbable global transcription activator SNF2L2CD22
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesGenentech Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A